SIG SAUER Announces U.S. Army Designates Type Classification Milestone For The NGSW Lethality Program
"This approval underscores the U.S. Army's commitment to equipping our soldiers with next generation lethality to maintain tactical superiority and enhance mission success," states Steve Rose, Executive Vice President, Defense Strategies Group. "The M7 and M250 represent a transformative leap in combat capability."
The NGSW Program, initiated in 2017, aims to revolutionize small arms capabilities for the U.S. Army. Following a 27-month prototype phase, extensive testing culminated in the selection of SIG SAUER's XM7 and XM250 in April 2022.
About SIG SAUER, Inc.:
SIG SAUER, Inc. is a leading provider and manufacturer of firearms, electro-optics, ammunition, airguns, suppressors, remote controlled weapons stations, and training. For over 250 years, SIG SAUER has evolved and thrived by blending American ingenuity, German engineering, and Swiss precision. Today, SIG SAUER is synonymous with industry-leading quality and innovation, which has made it the brand of choice amongst the U.S. Military, the global defense community, law enforcement, competitive shooters, hunters, and responsible citizens. Additionally, SIG SAUER is the premier provider of elite firearms instruction and tactical training at the SIG SAUER Academy. Headquartered in Newington, New Hampshire, SIG SAUER has over 3,400 employees across sixteen U.S. locations in three states, and four additional global facilities. SIG SAUER is certified a Great Place to WorkTM. For more information about the company and product line visit: sigsauer .
Media Contact:
Phil Strader
Vice President, Consumer Affairs
[email protected]
SOURCE SIG SAUER, Inc.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.

Comments
No comment